Citation:Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al 2015

From Cancer Guidelines Wiki

Citation


Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol 2015 Sep;26(9):1877-83 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/26141208.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?
What is the optimal systemic therapy regimen for patients with oncogenic driver mutations (including EGFR and ALK)?
What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?
Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC?